The wildlife TV star has hosted the BBC’s Springwatch nature show for 14 years, having previously worked on The Really Wild Show and Wide Awake Club.

She recently finished as runner-up on ITV reality show Dancing on Ice, competing last year with professional partner Mark Hanretty.

Michaela, who supports Oxford United through her son, who works at the club, had an exclusive chat with the Oxford Mail last week.

READ MORE: Leonardo DiCaprio buys £95m Cotswolds castle for mega movie deal

Michaela Strachan with a cheetah. (Image: Michaela Strachan / Not Just A Wild Life UK Tour)

The 59-year-old reflected on her time on Dancing on Ice and said: “It’s so funny that everyone else was more upset than me and Mark [about not winning].

“I mean, I was just so happy to get to the final, as I didn’t for one minute think when I started that I would get there- I thought I’d be lucky to get to round five.

“That’s what I was aiming for, so the fact that I got that far and to the last two couples ended with the Bolero, that was the win for me.

“It didn’t matter that I didn’t hold up the trophy at the end, hand on heart; it didn’t bother me. I was so proud of myself to have got that far.”

READ MORE: Wildlife TV legend praises Jeremy Clarkson over Clarkson’s Farm

Claudia Winkleman hosts The Traitors. (Image: Ian West / PA)

When asked if she would consider doing Strictly Come Dancing, Michaela said: “I don’t think there’s any secret that I’ve always wanted to do Strictly and I’ve never been asked.

“Dancing on Ice is a lot more challenging, as not only are you on ice, but you’re only allowed to be on it for two hours a day.

“So even during the live weeks when you’re trying to learn a new routine, you’re only rehearsing it two hours a day that week.

“You could do a lot of off-ice stuff obviously, but it also makes it much more challenging than Strictly because I think they rehearse eight hours a day sometimes.”

READ MORE: Michaela Strachan talks Springwatch and Chris Packham relationship

Michaela Strachan (Image: Michaela Strachan)

Speaking on potentially appearing on The Celebrity Traitors in the future, Michaela revealed: “I’d love to do Traitors.

“Honestly, that program is genius, and it’s such an entertaining watch, but I’m the worst liar in the world.”

Michaela laughed: “I’m so not good at lying, I’m way too honest and open.”

The 59-year-old was speaking ahead of her ‘Not Just a Wild Life’ live tour, which begins next month and features a date in nearby Newbury on Wednesday, April 29.

You can find more coverage from the Oxford Mail’s exclusive interview with Ms Strachan on our website in the coming days.

Supermarkets regularly reduce the price of food and drink items that are coming close to their best before, use by or display by dates, but shoppers aren’t happy with prices seen at the likes of Sainsbury’s and Tesco recently.

On Facebook, one customer shared a picture of a punnet of raspberries sold at Sainsbury’s with a yellow reduced-price sticker on it.

They said that raspberries being available for £2.50 at the normal price and reduced to £2.25 with the best before date of the next day was “ridiculous” and claimed it’s not the first time they’ve seen small reductions such as this.

What’s the difference between best before and use-by?

The caption of the post reads: “This is what I hate about Sainsbury’s, or at least my local Sainsbury’s in Cornwall.

“25p off!! there were loads of these as well as many other fruits and veg “reduced” with tomorrows date, they’ll end up in the bin out the back because of their pure greed!!

“It’s not just fruit and veg, my local store does these ridiculous reductions on everything!!”

Shoppers call out “ridiculous” reduced prices of fresh fruit

The post in the Bargain Lovers Facebook group, which has 1.2 million members, started a discussion with other members, with some agreeing that a day before a best before date, food should be reduced by more than 25p.

Some people said they’d seen similar price reductions in supermarkets other than Sainsbury’s.

This person commented: “Tesco the same especially the finest stuff”.

Another said: “Pointless them doing this!

“I’d rather pay the extra 25p for new and know they’ll last for longer”.

One shopper said: “They would rather chuck food than help, all stores the same .

“evil when people going hungry”.

However, some shoppers don’t think it’s a bad thing: “That’s not bad for tomorrow’s date, they’ll be reduced more tomorrow.”

Recommended reading:

Another customer said: “They get reduced further on the actual day”.

This person added: “No, they’ll be reduced further tomorrow and if they still don’t sell they’ll be collected by charity/food banks.”

Newsquest has contacted Sainsbury’s and Tesco for comment.

Do you think supermarkets should reduce the price of fresh products by more than 25p the day before the best before date? Let us know in the comments.

The NHS’s drugs watchdog, the National Institute for Health and Care Excellence (Nice), has approved the use of semaglutide for overweight and obese patients with specific heart and circulatory problems, in a bid to lower their risk of a serious cardiovascular event.

Marketed as Wegovy and produced by Novo Nordisk, the once‑weekly jab is a GLP‑1 receptor agonist that slows digestion, which in turn promotes weight loss.

Health officials estimate that around 1.2 million people in England could be eligible for the treatment.

How can Wegovy help deal with high BMI?

New guidance says the treatment can be used by patients with a body mass index (BMI) score of 27 or over in addition to other medicines, such as statins, and alongside a reduced-calorie diet and increased exercise to prevent heart attacks and strokes.

The move means there will be a rapid expansion of people eligible to take the drugs on the health service.

Health service officials said the treatment is set to be available on the NHS “within months”.

“We know that people who have already had a heart attack or stroke are living with real fear that it could happen again,” said Helen Knight, director of medicines evaluation at Nice.

“The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke.”

Helen Williams, national clinical director for cardiovascular disease prevention at NHS England, added: “For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing – offering a powerful new way to protect their hearts and improve their health.

“We know that people who have already had a heart attack or stroke face a much higher risk of having another.

“Used alongside a healthy diet and regular exercise, semaglutide could help prevent thousands of future major cardiovascular events and give many people the chance at a longer and healthier life.”

Health minister Sharon Hodgson said: “Weight loss drugs are proving to be a game changer in tackling obesity.

“Extending their use for people who also suffer from cardiovascular disease will be a lifesaver.”

Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, said: “So-called ‘weight loss drugs’ like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes.

“Today’s guidance will no doubt help save lives as cardiovascular disease is still one of the country’s biggest killers.”

How can Wegovy help stroke victims?

Juliet Bouverie, chief executive of the Stroke Association, said: “We always encourage people to reduce their risk of stroke by maintaining a healthy weight, but we understand this can be a challenge for some.

“As stroke survivors live with the worrying threat of further strokes, it’s vital they have options to help prevent that from happening, which suit their own circumstances.

“As many survivors can be left with disabilities which reduce movement, weight loss medication could be a suitable option for them, when recommended by a medical professional.”

Sebnem Avsar Tuna, general manager for Novo Nordisk UK, said the move was an “important step”, adding: “It means clinicians in England now have access to a further treatment that Nice has found to be cost effective, the first and only GLP-1 receptor agonist proven to reduce the risk of heart attack, stroke or cardiovascular death in this high risk population.”